Home Cannabis use, oral dysbiosis, and neurological disorders
Article Open Access

Cannabis use, oral dysbiosis, and neurological disorders

  • Amber A. Hazzard , Marice McCrorey , Tabinda Salman , Douglas E. Johnson , Zhenwu Luo , Xiaoyu Fu , Andrew P. Keegan , Andreana Benitez , Sylvia Fitting and Wei Jiang EMAIL logo
Published/Copyright: August 9, 2024
Download Article (PDF)
Become an author with De Gruyter Brill
Submit Manuscript Author Information
NeuroImmune Pharmacology and Therapeutics
From the journal NeuroImmune Pharmacology and Therapeutics Volume 3 Issue 3-4

Abstract

Cannabis (marijuana) is a leafy plant that has medical, recreational, and other uses. Cannabis is socially accepted and widely used throughout the United States. Though cannabis use is increasingly gaining popularity, studies detail the deleterious effects of chronic cannabis smoking on mental health, as well as the immunosuppressive properties of cannabinoids. Additionally, oral dysbiosis induced by cannabis smoking serves as a novel catalyst for neurological abnormalities, potentially possible through microbial translocation via the oral-brain axis. This review summarizes the effects and link of smoking cannabis on neurological abnormalities, immunity, and oral microbiome.

Keywords: cannabis; microbiome; dysbiosis; central nervous system; mental health

Introduction

Cannabis sativa (cannabis), commonly known as marijuana, is a leafy flowering plant that has long been cultivated in Central Asia [1]. Cannabis was utilized by Central Asians for dietary needs, such as a source of food, fiber, and oil, as well as for religious, medicinal, and recreational purposes [2]. Present-day, cannabis is commonly used medicinally and recreationally. Notably, cannabis use disorder (CUD) is also common. CUD is characterized by symptoms including excessive cannabis consumption, unsuccessful attempts to cut down or control use, continued use despite social or interpersonal issues, and tolerance or withdrawal symptoms [3]. The CUD rate in the United States more than doubled from 4.1 % between 2001 and 2002 to 9.5 % between 2012 and 2013 [4]. This stark increase in CUD coincides with more lenient cannabis legislation. In 2012, citizens of Colorado and Washington State voted to legalize the recreational use of cannabis. Today, 24 states and the District of Columbia have fully legalized cannabis, while many others have approved medicinal cannabis use and/or decriminalized possession of cannabis in small amounts [5]. This continued shift toward fully legalizing cannabis throughout the United States is leading to an increased prevalence of cannabis users [6]. With increased legalization, there is more opportunity for chronic cannabis abuse, especially when users are exposed to cannabis in their adolescence [7]. It is well-documented that acute cannabis use causes changes in neural activity and psychological behaviors [8–10]. Although the effects of cannabis use have been widely studied and reported, there are still conflicting views in the literature regarding chronic cannabis exposure. The beneficial and detrimental effects are highly debated throughout the medical and scientific community. In this review, we summarized current studies related to cannabis smoking, immunity, oral microbiome, and central nervous system (CNS) abnormalities.

Tetrahydrocannabinol (THC) is the primary psychoactive component in cannabis

Cannabis contains over 500 compounds, with over 60 being psychoactive cannabinoids [11]. Although many cannabinoids have now been identified, there are two main chemical constituents: tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is the primary psychoactive component of cannabis, while CBD is the primary non-psychoactive component [12]. Evidence confirms that THC influences both immune and neural responses [13]. The effects CBD has on the CNS, however, are more elusive. CBD has well-known anti-inflammatory and neuroprotective properties [14]. In fact, a drug comprised of CBD is now an FDA-approved treatment for two rare forms of epilepsy [15]. Alternatively, CBD can increase cytokine production under certain conditions and cause lipopolysaccharide (LPS)-induced pulmonary inflammation in vivo [16, 17]. In humans, side effects of CBD use include liver and male reproductive dysfunction [18]. Further research is necessary to fully understand the immunological effects of CBD. For this review, we will focus on the immunologic effects of THC.

THC exerts its effects by interacting with specific endocannabinoid system (ECS) endogenous cannabinoid (CB) receptors, CB1 and CB2. The ECS plays a central role in CNS development, synaptic plasticity, and both endogenous and exogenous challenges to the neuromodulatory system [19]. These proteins have been purified and shown to be G-protein-coupled 7-transmembrane receptors (GPCRs), which typically modulate neuronal activity by affecting second messengers (e.g., adenylate cyclase) [20, 21]. The CB1 receptor is considered to be the most abundant GPCR in the brain; the high distribution of the CB1 receptor in neurons accounts for the majority of cannabis-associated behavioral actions [22]. CB1 receptor signaling activity on neuronal membranes contributes to a fine-tuned control of synaptic efficacy and plasticity [23]. Meanwhile, the CB2 receptor is found predominantly in cells in the immune system. CB2 is most prevalent in macrophages, though it is also found at lower levels in the CNS, with abundant expression in microglial cells and astrocytes [24–26]. Microglia have known involvement in the maturation of the brain’s neocortex region, which plays a role in learning and memory [27]. In mice, prenatal THC exposure (PTE) caused alterations in microglia function that lasted into young adulthood, which affected the overall development of the neocortex in young adults. In addition, PTE was found to have long-lasting effects on the overall brain, olfactory bulb, and diencephalon volume [28]. Studies have shown that THC inhibits CB1/CB2 second messengers cyclic-adenosine monophosphate (cAMP) in a reversible manner, as well as adenylate cyclase activity via GPCR activity both in vitro and in mice [29, 30]. These findings indicate potential neuronal signaling pathways that are affected by THC exposure and warrant further research into THC effects on downstream signaling of cAMP and adenylate cyclase activity.

Studies suggest THC may also be involved with ion transport through interactions with transient receptor potential (TRP) channels [31]. TRPs consist of transmembrane proteins that respond to various chemical and physical stimuli [32]. TRPs are implicated in physiologic and pathophysiologic conditions in the CNS and have been connected to neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease [33]. THC was shown to be a functional agonist at the following TRP subsets in rats: TRPV2, TRPV3, TRPV4, and TRPM8 [34]. THC was not shown to influence TRPV1, however, which has analgesic effects [35]. THC interacting with TRPV2, TRPV3, TRPV4, and TRPM8 may contribute to the adverse effects of cannabis.

Chronic cannabis smoking negatively impacts mental health

The adverse effects of cannabis have been summarized in several reviews [36–40]. Cannabis users have reported biphasic psychological effects of THC: they may involve either euphoria and relaxation or dysphoria and anxiety, the outcome of which principally depends on the dose level [41, 42]. Frequent users showed blunted psychotomimetic effects, perceptual alteration, cognitive impairment, anxiogenesis, and cortisol increase [8]. When challenged with acute psychosocial stress, lower doses of THC were associated with euphoria and relaxation while higher dosages correlated with increased negative psychological responses [43]. Additional adverse effects of chronic cannabis use include negative impacts on mental health and promotion of psychosis.

Routine cannabis use is associated with an increased risk of anxiety and depression [44], though causality has not been established. Cannabis exacerbates the development of schizophrenia, especially among people who have a genetic vulnerability, and is associated with other psychoses [45]. It has also been previously reported that the inhalation of THC increases striatal dopamine, which is thought to be responsible for psychotic symptoms [46, 47]. Furthermore, high-frequency and high-potency cannabis are independent factors that lead to a significantly higher risk of psychosis [48, 49]. Intravenous administration of THC may result in psychotic symptoms in a dose-dependent manner [41]. Likewise, the age of onset of cannabis usage may also impact the occurrence of psychosis. Early onset of psychosis was found to be potentially age-dependent, where cannabis abuse before the age of 15 correlated with a higher risk of experiencing an early psychotic episode [50]. There is a strong association between cannabis use and the risk of psychosis for those who start using cannabis in early adolescence. This may be because the brain developmental processes at this stage increases sensitivity to cannabis [48, 51]. Although studies suggest some populations benefit from using cannabis [52, 53], the negative short and long-term effects of cannabis use on mental health cannot be ignored. Moreover, the risks of cannabis use are related to the extent of usage, drug potency, age of exposure, and several other factors [54].

Furthermore, serotonin receptor 1b (5-HTR1B) expression was found to be upregulated with short-term usage of cannabis, but long-term cannabis abuse resulted in significant 5-HTR1B downregulation and behavioral changes [55]. These findings further indicate the frequency of cannabis use as a risk factor in the development of psychoses symptoms. In addition, polymorphisms in 5-HTR1B were found to be associated with the risk of schizophrenia development [56], indicating that cannabis use may also exacerbate psychosis symptoms in predisposed individuals. Further studies into the potential gene regulatory effects of cannabis are warranted.

Cannabinoids are immunosuppressive

At the cellular level, cannabis exhibits immunosuppressive activity on several different immune cell types. Cannabinoids inhibited cytotoxic T lymphocytes (CTLs) by suppressing the cytotoxic activity [57] and lymphocyte maturation and differentiation [58]. Phytocannabinoids inhibited monocyte migration in isolated cells from cannabis users and expressed CB1 expression in monocytes [59]. Furthermore, cannabinoid receptor activation selectively inhibited the release of angiogenic factors from human lung macrophages [60], which could be explained by their reduced migratory function. Treatment of murine peritoneal macrophages with cannabis extracts has been shown to lead to impaired oxidative burst in response to LPS, which is characterized by down-regulated nitric oxide production and reduced levels of COX-2 and IL-1β [61]. The reduction of COX-2, cytokine production, and phagocytosis may account for impaired antimicrobial activity in alveolar macrophages from marijuana smokers in response to Staphylococcus aureus [62]. In this review, we summarize and discuss the immunosuppressive effects of THC.

THC can decrease the number of splenic dendritic cells (DCs), and alter the function of DCs by inhibiting MHC-II expression [63]. Consistently, THC is immunosuppressive and impairs host immune response to bacterial and viral infections. THC significantly inhibits natural killer (NK) cytotoxic activity, mediated by the CB1 and CB2 receptors [64]. Suppression of NK function was dependent on the concentration and duration of THC treatment [57, 65]. THC has also been shown to inhibit proliferation and induce apoptosis of other lymphocyte cell populations. Mice that received THC had significantly reduced proliferation of splenocytes following in vitro analysis of stimulating cells with anti-CD3 monoclonal antibody (mAb), Concanavalin A (ConA), and LPS in vitro [66]. In the same study, thymocytes, naive and activated splenocytes exposed to 10 mM or 20 mM of THC had significantly increased apoptosis in a dose-dependent manner [66]. Furthermore, THC decreased Bcl-2 and increased caspase-1 activity in naive and LPS-activated macrophages isolated from mouse splenocytes [67, 68]. Because THC and other cannabinoids induce apoptosis, inhibit cell proliferation, and suppress cytokine production, they are identified as anti-inflammatory molecules [69]. It is important to note, however, that patients with highly dysfunctional inflammatory activation (e.g., multiple sclerosis) may fail to exhibit the immunosuppressive effects of cannabis [70]. Outside of these conditions, the immunosuppressive effects of cannabis can decrease the robustness of the immune system.

The immunosuppressive effects of cannabinoids may lead to compromised immunologic competence in the respiratory system of cannabis smokers. This is indicated by an increased rate of respiratory infections and pneumonia [71, 72] and increased susceptibility to infection and poor outcomes of COVID-19 [73]. Cannabinoid-altered immunity depends on the duration of use; within the injured tissues, monocyte inflammatory responses were inhibited more extensively in individuals with chronic exposure to cannabis compared to short-term users or non-users [59]. Previous studies have demonstrated that THC treatment shifts the protective Th1 response to a non-protective Th2 response [74–76]. For example, Legionella pneumophila infection of mice induced IL-1, IL-12, and IFN-γ pro-inflammatory cytokines and Th1 immune response, whereas THC treatment prior to the infection suppressed immunity and early-stage IFN-γ, IL-12, and IL-12 receptor β2 responses during L. pneumophila infection [77]. More research is required to determine if the immunological suppression associated with chronic cannabis exposure can be reversed with cannabis extinction. Ultimately, the outcome of cannabis-induced inhibition of myeloid cell function may be an enhanced susceptibility to infectious disease and cancer in cannabis users.

The cytokine response to THC may contribute to immunosuppression

Cytokines can be a double-edged sword that promote antimicrobial defenses against infections while accelerating pathogenesis [78]. In response to THC, macrophages altered the cytokine network, leading to a shift in the Th1/Th2 cytokine profile [79]. The anti-inflammatory effect of THC and other cannabinoids suggests that cannabinoids might be useful in mitigating the symptoms of autoimmunity and chronic inflammatory diseases [80, 81]. However, some studies have shown contradictory results. For example, one study showed that individuals with cannabis use disorder had an impaired oxidative balance and elevated levels of pro-inflammatory cytokine, including IL-1β, IL-6, IL-8, and TNF-α [82]. Therefore, the dosage, duration, and components (THC vs. CBD) of cannabis usage may lead to varied thresholds in response to cannabinoids, which may explain some of the contradictory results of cannabinoid-altered immune response [83]. Unfortunately, it is difficult to clinically determine the extent or longevity of the immunosuppression induced by cannabis and its consequences. This challenge is primarily due to multiple confounders, such as cannabis users are likely to be multiple drug users (e.g., tobacco smoking, alcohol abuse). The effects of cannabis use on cytokine production and concurrent immune response warrant further studies.

Smoking cannabinoids induces oral dysbiosis

The oral microbiome is one of the many microbiomes in the human body and can influence health and disease. It is made up of expansive populations of bacteria, viruses, fungi, and other microbes that colonize surfaces in the oral cavity, including the gingiva, teeth, cheeks, and tongue [84]. Under homeostatic conditions, microbes compete for resources [85], and this competition limits the growth of opportunistic and pathogenic microbes, lowering the chances of infection and encouraging a mutualistic relationship with healthy hosts [86]. Additional protection is provided by the oral epithelium, such as the gingiva, which serves as a selectively permeable membrane that prevents microbes and their metabolites from entering the bloodstream [87]. However, external factors, such as smoking, can cause a deviation from the typical resident oral microbes. This shift, known as oral dysbiosis, leads to increased pathogenic bacteria, biofilm formation, and host systemic responses [88]. Overall, increased pathogenic bacteria and worsened systemic host response can damage the epithelium, thus allowing microbes and their metabolites to enter systemic circulation. Smoking cannabis causes deviations from homeostasis that negatively impact the oral environment (Figure 1).

Figure 1: Smoking cannabis can induce oral dysbiosis.
Figure 1:

Smoking cannabis can induce oral dysbiosis.

Smoking is the primary method for using cannabis [89]. Here, the smoking category does not include vaping. While vaping is becoming increasingly common, there is not yet enough data to comment on how the oral microbiome is affected by cannabis vaping exclusively. It is known, however, that smoking cannabis can change the oral environment. Cannabis users tend to show compromised oral health, with increased incidences of dental caries and periodontal diseases, increased rates of leukoedema, and increased prevalence and density of Candida albicans [82, 90]. Cannabis smoking may also act as a carcinogen. Specifically, cannabis smokers developed premalignant lesions in the oral mucosa with significantly increased decay on the surface of the teeth when compared to a non-cannabis-exposed control group [91]. A previous study of 903 participants from Dunedin and New Zealand found that cannabis smoking may be a risk factor for periodontal disease that is independent of the use of tobacco [92]. Oral bacteria have been linked to cardiovascular diseases, pre-term birth, and Alzheimer’s disease [93–95]. Therefore, the effects of cannabis on the oral environment can have a systemic impact. Based on these considerations, the oral microbiome that develops with cannabis use may modulate brain function directly through bacteria or product translocation into the brain or indirectly through pathways yet to be discovered.

Pathogens may use the oral-brain axis to access the CNS

The oral microbiome has the second most abundant bacterial population after the intestines. The Human Oral Microbiome Database (HOMD) currently has 774 oral bacterial species cataloged, with 58 % being officially named, 16 % cultivated but not yet named, and 26 % uncultivated [96]. These bacterial genomes are categorized into 18 phyla; Absconditabacteria (SR1), Actinobacteria, Bacteriodetes, Chlamydiae, Chlorobi, Chloroflexi, Euyarchaeota, Firmicutes, Fusobacteria, Grancilibacteria (GN02), Ignavibacteriae, Lentisphaerae, Proteobacteria, Saccharibacteria (TM7), Spirochetes, Synergistetes, Tenericutes, and WPS-2 [96]. While the oral microbiota themselves have been well characterized, more research into their influence on the body is needed.

Several studies have confirmed the existence of the gut-brain axis: a bidirectional communication pathway between the microbes of the gastrointestinal (GI) tract and the brain. Though the GI tract encompasses the mouth, esophagus, stomach, intestines, and anus, most current literature focuses on intestinal microbiota. This focus is likely because the intestines having the largest microbial population at 1012 cells per milliliter of intestinal constituents [97]. Gut dysbiosis has been connected to various CNS abnormalities, including migraines, depression, autism, schizophrenia, and Alzheimer’s disease [98, 99]. Based on these findings, it is reasonable to postulate that the microbiota of other body cavities in the GI tract can also influence CNS abnormalities. Emerging evidence supports the existence of an oral-brain axis, similar to the gut-brain axis, that bacteria and/or their products can utilize to impact the CNS.

Cannabis use may influence the ability of pathogens to access the oral-brain axis. As addressed above, a decrease in host resistance may be the consequence of the immunosuppressive action of cannabinoids on the functionality of macrophages, T lymphocytes, and NK cells. Little is known concerning the potential of cannabinoids other than THC and CBD to alter immune functionality. The documented evidence that THC decreases salvation via CB1 activation and thus alters the innate anti-microbial activity of saliva in vivo indicates that cannabis use presents a potential risk of decreased resistance to infections in humans [100]. Studies suggest that marijuana is a co-factor that can increase the severity of infection by microbial agents by altering the host resistance [101]. Therefore, the effects of cannabis use on increased pathogen susceptibility in hosts pose an additional increased risk to immunocompromised individuals such as HIV-positive individuals [102]. Further studies addressing the enhancement of disease in immunocompromised individuals are warranted.

Smoking cannabis may lead to cannabis stomatitis, which includes changes in the oral epithelium, leukoedema of the buccal mucosa, and hyperkeratosis [103, 104]. Furthermore, opportunistic infectious bacteria from the mouth or gut may escape to new colonization sites and modulate the local environment. For example, Arthrobacter spp. and Massilia timonae have been isolated in patients from blood, cerebrospinal fluid, and bone [105, 106]. In periodontal bacterial overgrowth, increased presence of opportunistic bacterial infections and decreased inflammatory signals are observed in oral epithelial cells [107] exposed to E-cigarette aerosols. This infers that an altered local environment may stimulate a shift in the bacterial response. Many studies have demonstrated that the microbiome, microbiota-derived products, and related factors are correlated with or modulate neuro-psychiatric and behavioral disorders [108–113]. Among these, Actinomyces meyeri has been shown to cause brain abscesses and other types of CNS infections [114, 115], indicating that this organism may contribute directly to CNS damage or neurological abnormalities.

Many nerves lead from the oronasal cavity directly to the brain, including the trigeminal and olfactory nerves. These nerve pathways initiate in the nasal cavity at the olfactory neurepithelium and terminate at the central nervous system, which provides a direct route for pathogenic infection of the brain (Figure 2). Drugs can be directly transported from the nose to the brain along the olfactory and trigeminal nerve pathways to overcome the blood-brain barrier (BBB) [116]. The trigeminal nerve is thought to provide a route of entry for oral bacteria into the brain in Alzheimer’s disease. Treponema pectinovorum and/or Treponema socranskii are found in trigeminal ganglia and pons in some Alzheimer patients, indicating that oral Treponema may infect the brain via branches of the trigeminal nerve [117]. Another potential route is the olfactory nerve. Neisseria meningitidis can pass directly from the nasopharynx to the meninges through the olfactory nerve system [118]. In Alzheimer’s disease, hyposmia or anosmia are considered heralding symptoms [119, 120]. Olfactory ensheathing cells have many capabilities of macrophages to provide bactericidal protection against invasion via the oronasal route. They can migrate and engulf bacteria and can be activated to express inducible nitric oxide synthase in response to bacterial infiltration [121]. However, in some cases, compromised olfactory ensheathing cells provide a vehicle for bacterial transport. For example, S. aureus is able to penetrate the immunological defense of the damaged olfactory mucosa and infiltrate into the olfactory bulb [122].

Figure 2: Bacteria translocation into the trigeminal and olfactory nerves of people with Alzheimer’s disease.
Figure 2:

Bacteria translocation into the trigeminal and olfactory nerves of people with Alzheimer’s disease.

Microbial dysbiosis negatively impacts mental health

Previous studies suggest that LPS, produced by Gram-negative bacteria, can disrupt the BBB. The BBB cells respond to bacterial products (e.g., LPS) via Toll-like receptors (TLRs) (e.g., TLR2, TLR3, TLR4, and TLR6) expressed on the membranes of the constituent cells or intracellular expressed cells. LPS binding to TLR4 has been shown to increase the permeability of leukemia inhibitor factor from the blood to the brain [123]. Furthermore, activation of TLR2/6 leads to downregulation of the expression of tight junction proteins, such as occluding and claudin-5, on the cell membrane, leading to an increased permeability of the BBB [124]. Peripheral cytokine signals are amplified in the CNS by local inflammatory networks, which include inflammatory signal transduction pathways and induction of local cytokine production. In the brain, vagal afferents have been shown to mediate sickness behavior in response to peripherally administered LPS and IL-1 [125]. Additionally, endothelial cells and perivascular macrophages respond to circulating cytokines to induce expression of COX-2 [126, 127], which leads to neuronal injury in the setting of excitotoxicity [128]. After stimulation, cytokines in the brain are primarily produced by microglia [129] but also can be produced by oligodendrocytes [130] and astrocytes [131]. However, after acute inflammatory stimulation, increased CNS cytokine levels may play a role in protecting the brain. At the same time, under chronic immune activation, microglia may provide a source of inflammatory mediators that influence the brain neurotransmitter system and neuronal integrity [132].

LPS can induce microglia activation in vivo and in vitro. Microglia enhance neuronal survival by releasing trophic and anti-inflammatory factors, regulating brain development by enforcing the programmed elimination of neural cells. Activated microglia can produce inducible NO synthase (iNOS), reactive oxygen and nitrogen species (ROS/RNS), and MCP-1/CCL2, a chemokine involved in attracting peripheral immune cells to the brain; once activated, microglia cause progressive tyrosine hydroxylase and dopamine neuron loss [133, 134] potentially leading to behavioral changes. LPS and typhoid vaccination have been shown to affect basal ganglia activity that regulates microglia activity at neuronal synapses [135, 136]. In animal studies, after acute immune activation induced by LPS, indoleamine 2,3-dioxygenase activity is significantly increased at 24 h and peaks at 48 h in response to LPS administration. 2,3-dioxygenase has been proposed to mediate comorbid depression in inflammatory disorders, in which 5-hydroxytryptamine (5-HT) and other monoamines are released in the hypothalamus to mediate fever and sickness behavior [137]. Acute administration of cytokines, such as IFN-γ, IL-1β, TNF-α, and IL-6, increases 5-HT release in several brain regions, which could be mediated by increased 5-HT activity in addition to the cytokine-induced changes in 5-HT metabolism [138, 139]. Administration of inflammatory cytokines acutely increases 5-HT turnover in brain regions such as the cortex and nucleus accumbens, and these changes occur in concert with the appearance of later, more persistent depressive-like behaviors. For these reasons, LPS is an important bacterial component that can impact mental health, especially during microbial dysbiosis.

While evidence has linked inflammatory cytokines to the development of neuropsychiatric symptoms such as anxiety and depression, cannabis is generally thought to have an anti-inflammatory effect. For this reason, the inflammatory cytokine-mediated effects of cannabis on the CNS have not been discussed.

Conclusions

Cannabis is the most widely used illicit drug in the world, with both therapeutic and recreational effects. However, chronic cannabis smoking can also have detrimental consequences on oral health and brain function. In this review, we have discussed the current documented effects smoking cannabis has on the immune system and brain function and development, which warrants further research into the risk factors associated with cannabis smoking. We highlighted evidence on how smoking cannabis alters the oral microbiome, leading to dysbiosis and increased levels of potentially harmful bacteria. We have also explored the possible mechanisms by which oral dysbiosis can affect the central nervous system through the oral-brain axis and contribute to cognitive impairment and neurodegenerative diseases, such as Alzheimer’s disease. Although the negative psychological and developmental risks associated with routine cannabis use are documented, there remains a strong push by researchers and medical doctors for its controlled use to treat psychosocial and inflammatory conditions in patients. However, this oral microbiome-centered connection between the brain and immune system warrants further immunological studies into the development of and risks of neuronal diseases associated with cannabis smoking.

Corresponding author: Wei Jiang, Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC, 29425, USA; Ralph H. Johnson VA Medical Center, Charleston, SC, 29403, USA; and Divison of Infectious Diseases, Department of Medicine, Medical University of South Carolina, 173 Ashley Ave. BSB214C, Charleston, SC, 29425, USA, E-mail: 

Funding source: Medical Research Service at the Ralph H. Johnson VA Medical Center

Award Identifier / Grant number: VA CSRD MERIT I01 CX-002422

Funding source: National Institute of General Medical Sciences

Award Identifier / Grant number: R25GM072643

Funding source: Intramural Research Program

Award Identifier / Grant number: R01DA045596

Award Identifier / Grant number: R01DA055523

Award Identifier / Grant number: R03DA057164

Acknowledgment

Figures created with BioRender.com.

  1. Research ethics: Not applicable.

  2. Informed consent: Not applicable.

  3. Author contributions: AH, ZL, MM and XF wrote the manuscript; SF, TS, DJ, AK and WJ revised the manuscript. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Competing interests: The authors state no conflict of interest.

  5. Research funding: This work was supported by grants from the National Institute on Drug Abuse R01DA045596 (Fitting), R03DA057164 (Jiang), R01DA055523 (Fitting & Jiang), the Medical Research Service at the Ralph H. Johnson VA Medical Center (merit grant VA CSRD MERIT I01 CX-002422, Jiang), NIH National Institute of General Medical Sciences R25GM072643 (Catrina Robinson).

  6. Data availability: Not applicable.

References

1. Russo, EB, Jiang, H-E, Li, X, Sutton, A, Carboni, A, del Bianco, F, et al.. Phytochemical and genetic analyses of ancient cannabis from Central Asia. J Exp Bot 2008;59:4171–82. https://doi.org/10.1093/jxb/ern260.Search in Google Scholar PubMed PubMed Central

2. Piluzza, G, Delogu, G, Cabras, A, Marceddu, S, Bullitta, S. Differentiation between fiber and drug types of hemp (Cannabis sativa L.) from a collection of wild and domesticated accessions. Genet Resour Crop Evol 2013;60:2331–42. https://doi.org/10.1007/s10722-013-0001-5.Search in Google Scholar

3. American Psychiatric Association, DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5TM, 5th ed. Arlington, VA: American Psychiatric Publishing, Inc.; 2013.10.1176/appi.books.9780890425596Search in Google Scholar

4. Hasin, DS, Saha, TD, Kerridge, BT, Goldstein, RB, Chou, SP, Zhang, H, et al.. Prevalence of marijuana use disorders in the United States between 2001–2002 and 2012–2013. JAMA Psychiatry 2015;72:1235–42. https://doi.org/10.1001/jamapsychiatry.2015.1858.Search in Google Scholar PubMed PubMed Central

5. Legislatures NCoS. State medical cannabis laws: NCSL; 2023. Available from: https://www.ncsl.org/health/state-medical-cannabis-laws#Body.Search in Google Scholar

6. Smart, R, Pacula, RL. Early evidence of the impact of cannabis legalization on cannabis use, cannabis use disorder, and the use of other substances: findings from state policy evaluations. Am J Drug Alcohol Abuse 2019;45:644–63. https://doi.org/10.1080/00952990.2019.1669626.Search in Google Scholar PubMed PubMed Central

7. Ladegard, K, Thurstone, C, Rylander, M. Marijuana legalization and youth. Pediatrics 2020;145:S165–74. https://doi.org/10.1542/peds.2019-2056d.Search in Google Scholar

8. D’Souza, DC, Ranganathan, M, Braley, G, Gueorguieva, R, Zimolo, Z, Cooper, T, et al.. Blunted psychotomimetic and amnestic effects of Δ-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 2008;33:2505–16. https://doi.org/10.1038/sj.npp.1301643.Search in Google Scholar PubMed PubMed Central

9. Ranganathan, M, D’Souza, DC. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology (Berl) 2006;188:425–44. https://doi.org/10.1007/s00213-006-0508-y.Search in Google Scholar PubMed

10. Batalla, A, Crippa, JA, Busatto, GF, Guimaraes, FS, Zuardi, AW, Valverde, O, et al.. Neuroimaging studies of acute effects of THC and CBD in humans and animals: a systematic review. Curr Pharm Des 2014;20:2168–85. https://doi.org/10.2174/13816128113199990432.Search in Google Scholar PubMed

11. Pertwee, R. Handbook of cannabis. Oxford: Oxford University Press; 2014.10.1093/acprof:oso/9780199662685.001.0001Search in Google Scholar

12. Izzo, AA, Borrelli, F, Capasso, R, Di Marzo, V, Mechoulam, R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009;30:515–27. https://doi.org/10.1016/j.tips.2009.07.006.Search in Google Scholar PubMed

13. Ashton, CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001;178:101–6. https://doi.org/10.1192/bjp.178.2.101.Search in Google Scholar PubMed

14. Zuardi, AW. Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action. Braz J Psychiatr 2008;30:271–80. https://doi.org/10.1590/s1516-44462008000300015.Search in Google Scholar PubMed

15. Administration FFaD. FDA approves first drug comprised of an active ingredient derived from marijuana to treat rare, severe forms of epilepsy. FDA; 2018. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-comprised-active-ingredient-derived-marijuana-treat-rare-severe-forms.Search in Google Scholar

16. Karmaus, PW, Wagner, JG, Harkema, JR, Kaminski, NE, Kaplan, BL. Cannabidiol (CBD) enhances lipopolysaccharide (LPS)-induced pulmonary inflammation in C57BL/6 mice. J Immunotoxicol 2013;10:321–8. https://doi.org/10.3109/1547691X.2012.741628.Search in Google Scholar PubMed PubMed Central

17. Chen, W, Kaplan, BL, Pike, ST, Topper, LA, Lichorobiec, NR, Simmons, SO, et al.. Magnitude of stimulation dictates the cannabinoid-mediated differential T cell response to HIVgp120. J Leukoc Biol 2012;92:1093–102. https://doi.org/10.1189/jlb.0212082.Search in Google Scholar PubMed PubMed Central

18. National Center for Complementary and Inegrative Health. Cannabis (Marijuana) and Cannabinoids: What You Need To Know: NIH NCCIH; 2019 Available from: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know.Search in Google Scholar

19. Lu, HC, Mackie, K. An introduction to the endogenous cannabinoid system. Biol Psychiatr 2016;79:516–25. https://doi.org/10.1016/j.biopsych.2015.07.028.Search in Google Scholar PubMed PubMed Central

20. Howlett, AC. Cannabinoid inhibition of adenylate cyclase. Biochemistry of the response in neuroblastoma cell membranes. Mol Pharmacol 1985;27:429–36.Search in Google Scholar

21. Howlett, AC. Cannabinoid receptor signalling. Handb Exp Pharmacol 2005;168:53–79. https://doi.org/10.1007/3-540-26573-2_2.Search in Google Scholar PubMed

22. Gobira, PH, Joca, SR, Moreira, FA. Roles of cannabinoid CB1 and CB2 receptors in the modulation of psychostimulant responses. Acta Neuropsychiatr 2024;36:67–77. https://doi.org/10.1017/neu.2022.23.Search in Google Scholar PubMed

23. Howlett, AC, Breivogel, CS, Childers, SR, Deadwyler, SA, Hampson, RE, Porrino, LJ. Cannabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology 2004;47:345–58. https://doi.org/10.1016/j.neuropharm.2004.07.030.Search in Google Scholar PubMed

24. Maresz, K, Carrier, EJ, Ponomarev, ED, Hillard, CJ, Dittel, BN. Modulation of the cannabinoid CB2 receptor in microglial cells in response to inflammatory stimuli. J Neurochem 2005;95:437–45. https://doi.org/10.1111/j.1471-4159.2005.03380.x.Search in Google Scholar PubMed

25. Onaivi, ES, Ishiguro, H, Gong, J-P, Patel, S, Meozzi, PA, Myers, L, et al.. Functional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depression. Ann N Y Acad Sci 2008;1139:434–49. https://doi.org/10.1196/annals.1432.036.Search in Google Scholar PubMed PubMed Central

26. Onaivi, ES, Ishiguro, H, Gong, J-P, Patel, S, Perchuk, A, Meozzi, PA, et al.. Discovery of the presence and functional expression of cannabinoid CB2 receptors in brain. Ann N Y Acad Sci 2006;1074:514–36. https://doi.org/10.1196/annals.1369.052.Search in Google Scholar PubMed

27. Anderson, SR, Vetter, ML. Developmental roles of microglia: a window into mechanisms of disease. Dev Dynam 2019;248:98–117. https://doi.org/10.1002/dvdy.1.Search in Google Scholar PubMed PubMed Central

28. Benevenuto, SGM, Domenico, MD, Yariwake, VY, Dias, CT, Mendes-da-Silva, C, Alves, NO, et al.. Prenatal exposure to cannabis smoke induces early and lasting damage to the brain. Neurochem Int 2022;160:105406. https://doi.org/10.1016/j.neuint.2022.105406.Search in Google Scholar PubMed

29. Castillo Pablo, E, Younts Thomas, J, Chávez Andrés, E, Hashimotodani, Y. Endocannabinoid signaling and synaptic function. Neuron 2012;76:70–81. https://doi.org/10.1016/j.neuron.2012.09.020.Search in Google Scholar PubMed PubMed Central

30. Ohno-Shosaku, T, Kano, M. Endocannabinoid-mediated retrograde modulation of synaptic transmission. Curr Opin Neurobiol 2014;29:1–8. https://doi.org/10.1016/j.conb.2014.03.017.Search in Google Scholar PubMed

31. Muller, C, Morales, P, Reggio, PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci 2019;11:487. https://doi.org/10.3389/fnmol.2018.00487.Search in Google Scholar PubMed PubMed Central

32. Morelli, MB, Amantini, C, Liberati, S, Santoni, M, Nabissi, M. TRP channels: new potential therapeutic approaches in CNS neuropathies. CNS Neurol Disord Drug Targets 2013;12:274–93. https://doi.org/10.2174/18715273113129990056.Search in Google Scholar PubMed

33. Muller, C, Morales, P, Reggio, PH. Cannabinoid ligands targeting TRP channels. Front Mol Neurosci 2019;11:487. https://doi.org/10.3389/fnmol.2018.00487.Search in Google Scholar

34. De Petrocellis, L, Ligresti, A, Moriello, AS, Allarà, M, Bisogno, T, Petrosino, S, et al.. Effects of cannabinoids and cannabinoid-enriched Cannabis extracts on TRP channels and endocannabinoid metabolic enzymes. Br J Pharmacol 2011;163:1479–94. https://doi.org/10.1111/j.1476-5381.2010.01166.x.Search in Google Scholar PubMed PubMed Central

35. Wong, GY, Gavva, NR. Therapeutic potential of vanilloid receptor TRPV1 agonists and antagonists as analgesics: Recent advances and setbacks. Brain Res Rev 2009;60:267–77. https://doi.org/10.1016/j.brainresrev.2008.12.006.Search in Google Scholar PubMed

36. Campbell, FA, Tramèr, MR, Carroll, D, Reynolds, DJM, Moore, RA, McQuay, HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ 2001;323:13. https://doi.org/10.1136/bmj.323.7303.13.Search in Google Scholar PubMed PubMed Central

37. Hall, W, Solowij, N. Adverse effects of cannabis. Lancet 1998;352:1611–6. https://doi.org/10.1016/s0140-6736(98)05021-1.Search in Google Scholar PubMed

38. Kalant, H. Adverse effects of cannabis on health: an update of the literature since 1996. Prog Neuro Psychopharmacol Biol Psychiatr 2004;28:849–63. https://doi.org/10.1016/j.pnpbp.2004.05.027.Search in Google Scholar PubMed

39. Thomas, H. A community survey of adverse effects of cannabis use. Drug Alcohol Depend 1996;42:201–7. https://doi.org/10.1016/s0376-8716(96)01277-x.Search in Google Scholar PubMed

40. Wang, T, Collet, J-P, Shapiro, S, Ware, MA. Adverse effects of medical cannabinoids: a systematic review. Can Med Assoc J 2008;178:1669. https://doi.org/10.1503/cmaj.071178.Search in Google Scholar PubMed PubMed Central

41. D’Souza, DC, Perry, E, MacDougall, L, Ammerman, Y, Cooper, T, Wu, YT, et al.. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 2004;29:1558–72. https://doi.org/10.1038/sj.npp.1300496.Search in Google Scholar PubMed

42. Wade, DT, Robson, P, House, H, Makela, P, Aram, J. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil 2003;17:21–9. https://doi.org/10.1191/0269215503cr581oa.Search in Google Scholar PubMed

43. Childs, E, Lutz, JA, de Wit, H. Dose-related effects of delta-9-THC on emotional responses to acute psychosocial stress. Drug Alcohol Depend 2017;177:136–44. https://doi.org/10.1016/j.drugalcdep.2017.03.030.Search in Google Scholar PubMed PubMed Central

44. Patton, GC, Coffey, C, Carlin, JB, Degenhardt, L, Lynskey, M, Hall, W. Cannabis use and mental health in young people: cohort study. BMJ 2002;325:1195. https://doi.org/10.1136/bmj.325.7374.1195.Search in Google Scholar PubMed PubMed Central

45. Caspi, A, Moffitt, TE, Cannon, M, McClay, J, Murray, R, Harrington, H, et al.. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the Catechol-O-Methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol Psychiatr 2005;57:1117–27. https://doi.org/10.1016/j.biopsych.2005.01.026.Search in Google Scholar PubMed

46. Bossong, MG, van Berckel, BNM, Boellaard, R, Zuurman, L, Schuit, RC, Windhorst, AD, et al.. Δ9-Tetrahydrocannabinol induces dopamine release in the human striatum. Neuropsychopharmacology 2009;34:759–66. https://doi.org/10.1038/npp.2008.138.Search in Google Scholar PubMed

47. Kapur, S, Mizrahi, R, Li, M. From dopamine to salience to psychosis–linking biology, pharmacology and phenomenology of psychosis. Schizophr Res 2005;79:59–68. https://doi.org/10.1016/j.schres.2005.01.003.Search in Google Scholar PubMed

48. Casadio, P, Fernandes, C, Murray, RM, Di Forti, M. Cannabis use in young people: the risk for schizophrenia. Neurosci Biobehav Rev 2011;35:1779–87. https://doi.org/10.1016/j.neubiorev.2011.04.007.Search in Google Scholar PubMed

49. Di Forti, M, Morgan, C, Dazzan, P, Pariante, C, Mondelli, V, Marques, TR, et al.. High-potency cannabis and the risk of psychosis. Br J Psychiatry 2009;195:488–91. https://doi.org/10.1192/bjp.bp.109.064220.Search in Google Scholar PubMed PubMed Central

50. Pardo, M, Matali, JL, Sivoli, J, Regina, VB, Butjosa, A, Dolz, M, et al.. Early onset psychosis and cannabis use: prevalence, clinical presentation and influence of daily use. Asian J Psychiatr 2021;62:102714. https://doi.org/10.1016/j.ajp.2021.102714.Search in Google Scholar PubMed

51. Andersen, SL. Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 2003;27:3–18. https://doi.org/10.1016/s0149-7634(03)00005-8.Search in Google Scholar PubMed

52. Orsolini, L, Chiappini, S, Volpe, U, Berardis, D, Latini, R, Papanti, GD, et al.. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina (Kaunas) 2019;55:525. https://doi.org/10.3390/medicina55090525.Search in Google Scholar PubMed PubMed Central

53. MacCallum, CA, Russo, EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med 2018;49:12–19. https://doi.org/10.1016/j.ejim.2018.01.004.Search in Google Scholar PubMed

54. Di Forti, M, Sallis, H, Allegri, F, Trotta, A, Ferraro, L, Stilo, SA, et al.. Daily use, especially of high-potency cannabis, drives the earlier onset of psychosis in cannabis users. Schizophr Bull 2014;40:1509–17. https://doi.org/10.1093/schbul/sbt181.Search in Google Scholar PubMed PubMed Central

55. Dosumu, OA, Taiwo, OA, Akinloye, OA, Obadina, AO, Rotimi, SO, Owolabi, OP, et al.. Implications of Cannabis sativa on serotonin receptors 1B (HTR1B) and 7 (HTR7) genes in modulation of aggression and depression. Vegetos 2021;35:19–25. https://doi.org/10.1007/s42535-021-00308-9.Search in Google Scholar

56. Xia, X, Ding, M, Xuan, JF, Xing, JX, Pang, H, Wang, BJ, et al.. Polymorphisms in the human serotonin receptor 1B (HTR1B) gene are associated with schizophrenia: a case control study. BMC Psychiatr 2018;18:303. https://doi.org/10.1186/s12888-018-1849-x.Search in Google Scholar PubMed PubMed Central

57. Karmaus, PWF, Chen, W, Kaplan, BLF, Kaminski, NE. Δ9-Tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB2, disrupting early activation events. J Neuroimmune Pharmacol 2012;7:843–55. https://doi.org/10.1007/s11481-011-9293-4.Search in Google Scholar PubMed PubMed Central

58. Klein, TW, Kawakami, Y, Newton, C, Friedman, H. Marijuana components suppress induction and cytolytic function of murine cytotoxic T cells in vitro and in vivo. J Toxicol Environ Health 1991;32:465–77. https://doi.org/10.1080/15287399109531496.Search in Google Scholar PubMed

59. Sexton, M, Silvestroni, A, Moller, T, Stella, N. Differential migratory properties of monocytes isolated from human subjects naive and non-naive to Cannabis. Inflammopharmacology 2013;21:253–9. https://doi.org/10.1007/s10787-012-0133-9.Search in Google Scholar PubMed PubMed Central

60. Staiano, RI, Loffredo, S, Borriello, F, Iannotti, FA, Piscitelli, F, Orlando, P, et al.. Human lung-resident macrophages express CB1 and CB2 receptors whose activation inhibits the release of angiogenic and lymphangiogenic factors. J Leukoc Biol 2016;99:531–40. https://doi.org/10.1189/jlb.3hi1214-584r.Search in Google Scholar PubMed PubMed Central

61. Romano, B, Pagano, E, Orlando, P, Capasso, R, Cascio, MG, Pertwee, R, et al.. Pure Δ9-tetrahydrocannabivarin and a Cannabis sativa extract with high content in Δ9-tetrahydrocannabivarin inhibit nitrite production in murine peritoneal macrophages. Pharmacol Res 2016;113–(Pt A):199–208.10.1016/j.phrs.2016.07.045Search in Google Scholar PubMed

62. Shay, AH, Choi, R, Whittaker, K, Salehi, K, Kitchen, CMR, Tashkin, DP, et al.. Impairment of antimicrobial activity and nitric oxide production in alveolar macrophages from smokers of marijuana and cocaine. J Infect Dis 2003;187:700–4. https://doi.org/10.1086/368370.Search in Google Scholar PubMed

63. Karmaus, PWF, Chen, W, Crawford, R, Kaplan, BLF, Kaminski, NE. Δ9-Tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2. Toxicol Sci 2013;131:419–33. https://doi.org/10.1093/toxsci/kfs315.Search in Google Scholar PubMed PubMed Central

64. Massi, P, Fuzio, D, Viganò, D, Sacerdote, P, Parolaro, D. Relative involvement of cannabinoid CB1 and CB2 receptors in the Δ9-tetrahydrocannabinol-induced inhibition of natural killer activity. Eur J Pharmacol 2000;387:343–7. https://doi.org/10.1016/s0014-2999(99)00860-2.Search in Google Scholar PubMed

65. Specter, SC, Klein, TW, Newton, C, Mondragon, M, Widen, R, Friedman, H. Marijuana effects on immunity: suppression of human natural killer cell activity by delta-9-tetrahydrocannabinol. Int J Immunopharm 1986;8:741–5. https://doi.org/10.1016/0192-0561(86)90010-x.Search in Google Scholar PubMed

66. McKallip, RJ, Lombard, C, Martin, BR, Nagarkatti, M, Nagarkatti, PS. Δ9-Tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. J Pharmacol Exp Therapeut 2002;302:451. https://doi.org/10.1124/jpet.102.033506.Search in Google Scholar PubMed

67. Zhu, W, Friedman, H, Klein, TW. Δ9-Tetrahydrocannabinol induces apoptosis in macrophages and lymphocytes: involvement of Bcl-2 and caspase-1. J Pharmacol Exp Therapeut 1998;286:1103.10.1016/S0022-3565(24)37693-1Search in Google Scholar

68. McKallip, RJ, Lombard, C, Martin, BR, Nagarkatti, M, Nagarkatti, PS. Delta(9)-tetrahydrocannabinol-induced apoptosis in the thymus and spleen as a mechanism of immunosuppression in vitro and in vivo. (0022-3565 (Print)).Search in Google Scholar

69. Nagarkatti, P, Pandey, R, Rieder, SA, Hegde, VL, Nagarkatti, M. Cannabinoids as novel anti-inflammatory drugs. Future Med Chem 2009;1:1333–49. https://doi.org/10.4155/fmc.09.93.Search in Google Scholar PubMed PubMed Central

70. Lima, MG, Tardelli, VS, Brietzke, E, Fidalgo, TM. Cannabis and inflammatory mediators. Eur Addiction Res 2021;27:16–24. https://doi.org/10.1159/000508840.Search in Google Scholar PubMed

71. Owen, KP, Sutter, ME, Albertson, TE. Marijuana: respiratory tract effects. Clin Rev Allergy Immunol 2014;46:65–81. https://doi.org/10.1007/s12016-013-8374-y.Search in Google Scholar PubMed

72. Tashkin, DP. Increasing cannabis use: what we still need to know about its effects on the lung. Respirology 2014;19:619–20. https://doi.org/10.1111/resp.12308.Search in Google Scholar PubMed

73. Huang, D, Xu, R, Na, R. Cannabis use is associated with lower COVID-19 susceptibility but poorer survival. Front Public Health 2022;10:829715. https://doi.org/10.3389/fpubh.2022.829715.Search in Google Scholar PubMed PubMed Central

74. Mosmann, TR, Coffman, RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145–73. https://doi.org/10.1146/annurev.immunol.7.1.145.Search in Google Scholar

75. Newton, CA, Klein, TW, Friedman, H. Secondary immunity to Legionella pneumophila and Th1 activity are suppressed by delta-9-tetrahydrocannabinol injection. Infect Immun 1994;62:4015–20. https://doi.org/10.1128/iai.62.9.4015-4020.1994.Search in Google Scholar PubMed PubMed Central

76. Klein, TW, Newton, CA, Nakachi, N, Friedman, H. Δ9-Tetrahydrocannabinol treatment suppresses immunity and early IFN-γ, IL-12, and IL-12 receptor β2 responses to Legionella pneumophila infection. J Immunol 2000;164:6461–6. https://doi.org/10.4049/jimmunol.164.12.6461.Search in Google Scholar PubMed

77. Newton, CA, Chou, P-J, Perkins, I, Klein, TW. CB1 and CB2 cannabinoid receptors mediate different aspects of delta-9-tetrahydrocannabinol (THC)-induced T helper cell shift following immune activation by Legionella pneumophila infection. J Neuroimmune Pharmacol 2009;4:92–102. https://doi.org/10.1007/s11481-008-9126-2.Search in Google Scholar PubMed

78. Leonard, WJ, Lin, JX. Strategies to therapeutically modulate cytokine action. Nat Rev Drug Discov 2023;22:827–54. https://doi.org/10.1038/s41573-023-00746-x.Search in Google Scholar PubMed

79. Newton, C, Klein, T, Friedman, H. The role of macrophages in THC-induced alteration of the cytokine network. Adv Exp Med Biol 1998;437:207–14. https://doi.org/10.1007/978-1-4615-5347-2_23.Search in Google Scholar PubMed

80. Aziz, AI, Nguyen, LC, Oumeslakht, L, Bensussan, A, Ben Mkaddem, S. Cannabinoids as immune system modulators: cannabidiol potential therapeutic approaches and limitations. Cannabis Cannabinoid Res 2023;8:254–69. https://doi.org/10.1089/can.2022.0133.Search in Google Scholar PubMed

81. Holloman, BA-O, Nagarkatti, MA-O, Nagarkatti, PA-O. Epigenetic regulation of cannabinoid-mediated attenuation of inflammation and its impact on the use of cannabinoids to treat autoimmune diseases. https://doi.org/10.3390/ijms22147302.Search in Google Scholar PubMed PubMed Central

82. Moalic, E, Gestalin, A, Quinio, D, Gest, PE, Zerilli, A, Le Flohic, AM. The extent of oral fungal flora in 353 students and possible relationships with dental caries. Caries Res 2001;35:149–55. https://doi.org/10.1159/000047447.Search in Google Scholar PubMed

83. Freeman, TP, Craft, S, Wilson, J, Stylianou, S, ElSohly, M, Di Forti, M, et al.. Changes in delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) concentrations in cannabis over time: systematic review and meta-analysis. Addiction 2021;116:1000–10. https://doi.org/10.1111/add.15253.Search in Google Scholar PubMed

84. Dewhirst, FE, Chen, T, Izard, J, Paster, BJ, Tanner, AC, Yu, W-H, et al.. The human oral microbiome. J Bacteriol 2010;192:5002–17. https://doi.org/10.1128/JB.00542-10.Search in Google Scholar PubMed PubMed Central

85. Miller, DP, Fitzsimonds, ZR, Lamont, RJ. Metabolic signaling and spatial interactions in the oral polymicrobial community. J Dent Res 2019;98:1308–14. https://doi.org/10.1177/0022034519866440.Search in Google Scholar PubMed PubMed Central

86. Marsh, PD, Head, DA, Devine, DA. Ecological approaches to oral biofilms: control without killing. Caries Res 2015;49(Suppl 1):46–54. https://doi.org/10.1159/000377732.Search in Google Scholar PubMed

87. Wang, SS, Tang, YL, Pang, X, Zheng, M, Tang, YJ, Liang, XH. The maintenance of an oral epithelial barrier. Life Sci 2019;227:129–36. https://doi.org/10.1016/j.lfs.2019.04.029.Search in Google Scholar PubMed

88. Marsh, PD, Moter, A, Devine, DA. Dental plaque biofilms: communities, conflict and control. Periodontol 2000 2011;55:16–35. 10.1111/j.1600-0757.2009.00339.xSearch in Google Scholar PubMed

89. Schauer, GL, King, BA, Bunnell, RE, Promoff, G, McAfee, TA. Toking, vaping, and eating for health or fun: marijuana use patterns in adults, U.S., 2014. Am J Prev Med 2016;50:1–8.10.1016/j.amepre.2015.05.027Search in Google Scholar PubMed

90. Darling, MR, Arendorf, TM, Coldrey, NA. Effect of cannabis use on oral candidal carriage. J Oral Pathol Med 1990;19:319–21. https://doi.org/10.1111/j.1600-0714.1990.tb00852.x.Search in Google Scholar PubMed

91. Schulz-Katterbach, M, Imfeld, T, Imfeld, C. Cannabis and caries–does regular cannabis use increase the risk of caries in cigarette smokers? Schweiz Monatsschr Zahnmed 2009;119:576–83.Search in Google Scholar

92. Thomson, WM, Poulton, R, Broadbent, JM, Moffitt, TE, Caspi, A, Beck, JD, et al.. Cannabis smoking and periodontal disease among young adults. JAMA 2008;299:525–31. https://doi.org/10.1001/jama.299.5.525.Search in Google Scholar PubMed PubMed Central

93. Dominy, SS, Lynch, C, Ermini, F, Benedyk, M, Marczyk, A, Konradi, A, et al.. Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 2019;5:eaau3333. https://doi.org/10.1126/sciadv.aau3333.Search in Google Scholar PubMed PubMed Central

94. Shira Davenport, E. Preterm low birthweight and the role of oral bacteria. J Oral Microbiol 2010;2. https://doi.org/10.3402/jom.v2i0.5779.Search in Google Scholar PubMed PubMed Central

95. Leishman, SJ, Do, HL, Ford, PJ. Cardiovascular disease and the role of oral bacteria. J Oral Microbiol 2010;2. https://doi.org/10.3402/jom.v2i0.5781.Search in Google Scholar PubMed PubMed Central

96. Expanded human oral microbiome database [Internet]. eHOMD. [cited 2023]. Available from: https://homd.org/.Search in Google Scholar

97. O’Hara, AM, Shanahan, F. The gut flora as a forgotten organ. EMBO Rep 2006;7:688–93. https://doi.org/10.1038/sj.embor.7400731.Search in Google Scholar PubMed PubMed Central

98. Cenit, MC, Sanz, Y, Codoñer-Franch, P. Influence of gut microbiota on neuropsychiatric disorders. World J Gastroenterol 2017;23:5486–98. https://doi.org/10.3748/wjg.v23.i30.5486.Search in Google Scholar PubMed PubMed Central

99. Arzani, M, Jahromi, SR, Ghorbani, Z, Vahabizad, F, Martelletti, P, Ghaemi, A, et al.. Gut-brain axis and migraine headache: a comprehensive review. J Headache Pain 2020;21:15. https://doi.org/10.1186/s10194-020-1078-9.Search in Google Scholar PubMed PubMed Central

100. Andreis, K, Billingsley, J, Naimi Shirazi, K, Wager-Miller, J, Johnson, C, Bradshaw, H, et al.. Cannabinoid CB1 receptors regulate salivation. Sci Rep 2022;12:14182. https://doi.org/10.1038/s41598-022-17987-2.Search in Google Scholar PubMed PubMed Central

101. Lee, HL, Jung, KM, Fotio, Y, Squire, E, Palese, F, Lin, L, et al.. Frequent low-dose delta(9)-tetrahydrocannabinol in adolescence disrupts microglia homeostasis and disables responses to microbial infection and social stress in young adulthood. Biol Psychiatr 2022;92:845–60. https://doi.org/10.1016/j.biopsych.2022.04.017.Search in Google Scholar PubMed PubMed Central

102. Wenger, DS, Crothers, K. Marijuana smoking in men with HIV infection: a cause for concern. E Clinical Medicine 2019;7:5–6. https://doi.org/10.1016/j.eclinm.2019.01.016.Search in Google Scholar PubMed PubMed Central

103. Darling, MR, Arendorf, TM. Effects of cannabis smoking on oral soft tissues. Community Dent Oral Epidemiol 1993;21:78–81. https://doi.org/10.1111/j.1600-0528.1993.tb00725.x.Search in Google Scholar PubMed

104. Rawal, SY, Tatakis, DN, Tipton, DA. Periodontal and oral manifestations of marijuana use. J Tenn Dent Assoc 2012;92:26–31; quiz 31–2.Search in Google Scholar

105. Lindquist, D, Murrill, D, Burran, WP, Winans, G, Janda, JM, Probert, W. Characteristics of Massilia timonae and Massilia timonae-like isolates from human patients, with an emended description of the species. J Clin Microbiol 2003;41:192–6. https://doi.org/10.1128/jcm.41.1.192-196.2003.Search in Google Scholar PubMed PubMed Central

106. Mages Irene, S, Frodl, R, Bernard Kathryn, A, Funke, G. Identities of Arthrobacter spp. and Arthrobacter-like bacteria encountered in human clinical specimens. J Clin Microbiol 2008;46:2980–6. https://doi.org/10.1128/jcm.00658-08.Search in Google Scholar

107. Catala-Valentin, AR, Almeda, J, Bernard, JN, Cole, AM, Cole, AL, Moore, SD, et al.. E-cigarette aerosols promote oral S. aureus colonization by delaying an immune response and bacterial clearing. Cells 2022;11:773. https://doi.org/10.3390/cells11050773.Search in Google Scholar PubMed PubMed Central

108. Wang, Y, Kasper, LH. The role of microbiome in central nervous system disorders. Brain Behav Immun 2014;38:1–12. https://doi.org/10.1016/j.bbi.2013.12.015.Search in Google Scholar PubMed PubMed Central

109. Ohland, CL, Kish, L, Bell, H, Thiesen, A, Hotte, N, Pankiv, E, et al.. Effects of Lactobacillus helveticus on murine behavior are dependent on diet and genotype and correlate with alterations in the gut microbiome. Psychoneuroendocrinology 2013;38:1738–47. https://doi.org/10.1016/j.psyneuen.2013.02.008.Search in Google Scholar PubMed

110. Mulle, JG, Sharp, WG, Cubells, JF. The gut microbiome: a new frontier in autism research. Curr Psychiatry Rep 2013;15:337. https://doi.org/10.1007/s11920-012-0337-0.Search in Google Scholar PubMed PubMed Central

111. Gareau, MG, Wine, E, Rodrigues, DM, Cho, JH, Whary, MT, Philpott, DJ, et al.. Bacterial infection causes stress-induced memory dysfunction in mice. Gut 2011;60:307–17. https://doi.org/10.1136/gut.2009.202515.Search in Google Scholar PubMed

112. Gareau, MG, Jury, J, MacQueen, G, Sherman, PM, Perdue, MH. Probiotic treatment of rat pups normalises corticosterone release and ameliorates colonic dysfunction induced by maternal separation. Gut 2007;56:1522–8. https://doi.org/10.1136/gut.2006.117176.Search in Google Scholar PubMed PubMed Central

113. Arseneault-Bréard, J, Rondeau, I, Gilbert, K, Girard, S-A, Tompkins, TA, Godbout, R, et al.. Combination of Lactobacillus helveticus R0052 and Bifidobacterium longum R0175 reduces post-myocardial infarction depression symptoms and restores intestinal permeability in a rat model. (1475-2662 (Electronic)).Search in Google Scholar

114. Smego, RAJr. Actinomycosis of the central nervous system. Rev Infect Dis 1987;9:855–65. https://doi.org/10.1093/clinids/9.5.855.Search in Google Scholar PubMed

115. Könönen, E, Wade, WG. Actinomyces and related organisms in human infections. Clin Microbiol Rev 2015;28:419–42. https://doi.org/10.1128/cmr.00100-14.Search in Google Scholar PubMed PubMed Central

116. Pardeshi, CV, Belgamwar, VS. Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood–brain barrier: an excellent platform for brain targeting. Expet Opin Drug Deliv 2013;10:957–72. https://doi.org/10.1517/17425247.2013.790887.Search in Google Scholar PubMed

117. Riviere, GR, Riviere, KH, Smith, KS. Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer’s disease. Oral Microbiol Immunol 2002;17:113–8. https://doi.org/10.1046/j.0902-0055.2001.00100.x.Search in Google Scholar PubMed

118. Sjölinder, H, Jonsson, A-B. Olfactory nerve–a novel invasion route of Neisseria meningitidis to reach the meninges. PLoS One 2010;5:e14034. https://doi.org/10.1371/journal.pone.0014034.Search in Google Scholar PubMed PubMed Central

119. Christen-Zaech, S, Kraftsik, R, Pillevuit, O, Kiraly, M, Martins, R, Khalili, K, et al.. Early olfactory involvement in Alzheimer’s disease. Can J Neurol Sci 2003;30:20–5. https://doi.org/10.1017/s0317167100002389.Search in Google Scholar PubMed

120. Conti, MZ, Vicini-Chilovi, B, Riva, M, Zanetti, M, Liberini, P, Padovani, A, et al.. Odor identification deficit predicts clinical conversion from mild cognitive impairment to dementia due to Alzheimer’s disease. Arch Clin Neuropsychol 2013;28:391–9. https://doi.org/10.1093/arclin/act032.Search in Google Scholar PubMed

121. Harris, JA, West, AK, Chuah, MI. Olfactory ensheathing cells: nitric oxide production and innate immunity. Glia 2009;57:1848–57. https://doi.org/10.1002/glia.20899.Search in Google Scholar PubMed

122. Herbert, RP, Harris, J, Chong, KP, Chapman, J, West, AK, Chuah, MI. Cytokines and olfactory bulb microglia in response to bacterial challenge in the compromised primary olfactory pathway. J Neuroinflammation 2012;9:109. https://doi.org/10.1186/1742-2094-9-109.Search in Google Scholar PubMed PubMed Central

123. Pan, W, Yu, C, Hsuchou, H, Zhang, Y, Kastin, AJ. Neuroinflammation facilitates LIF entry into brain: role of TNF. Am J Physiol Cell Physiol 2008;294:C1436–2. https://doi.org/10.1152/ajpcell.00489.2007.Search in Google Scholar PubMed PubMed Central

124. Nagyőszi, P, Wilhelm, I, Farkas, AE, Fazakas, C, Dung, NTK, Haskó, J, et al.. Expression and regulation of toll-like receptors in cerebral endothelial cells. Neurochem Int 2010;57:556–64. https://doi.org/10.1016/j.neuint.2010.07.002.Search in Google Scholar PubMed

125. Dantzer, R, Konsman, J-P, Bluthé, R-M, Kelley, KW. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent? Auton Neurosci 2000;85:60–5. https://doi.org/10.1016/s1566-0702(00)00220-4.Search in Google Scholar PubMed

126. Konsman, JP, Parnet, P, Dantzer, R. Cytokine-induced sickness behaviour: mechanisms and implications. Trends Neurosci 2002;25:154–9. https://doi.org/10.1016/s0166-2236(00)02088-9.Search in Google Scholar PubMed

127. Serrats, J, Schiltz, JC, García-Bueno, B, van Rooijen, N, Reyes, TM, Sawchenko, PE. Dual roles for perivascular macrophages in immune-to-brain signaling. Neuron 2010;65:94–106. https://doi.org/10.1016/j.neuron.2009.11.032.Search in Google Scholar PubMed PubMed Central

128. Liang, X, Wu, L, Wang, Q, Hand, T, Bilak, M, McCullough, L, et al.. Function of COX-2 and prostaglandins in neurological disease. J Mol Neurosci 2007;33:94–9. https://doi.org/10.1007/s12031-007-0058-8.Search in Google Scholar PubMed

129. Smith, JA, Das, A, Ray, SK, Banik, NL. Role of pro-inflammatory cytokines released from microglia in neurodegenerative diseases. Brain Res Bull 2012;87:10–20. https://doi.org/10.1016/j.brainresbull.2011.10.004.Search in Google Scholar PubMed PubMed Central

130. Peferoen, L, Kipp, M, van der Valk, P, van Noort, JM, Amor, S. Oligodendrocyte-microglia cross-talk in the central nervous system. Immunology 2014;141:302–13. https://doi.org/10.1111/imm.12163.Search in Google Scholar PubMed PubMed Central

131. Choi, SS, Lee, HJ, Lim, I, Satoh, J, Kim, SU. Human astrocytes: secretome profiles of cytokines and chemokines. PLoS One 2014;9:e92325. https://doi.org/10.1371/journal.pone.0092325.Search in Google Scholar PubMed PubMed Central

132. Klein, RS, Hunter, CA. Protective and pathological immunity during central nervous system infections. Immunity 2017;46:891–909. https://doi.org/10.1016/j.immuni.2017.06.012.Search in Google Scholar PubMed PubMed Central

133. Ling, Z, Gayle, DA, Ma, SY, Lipton, JW, Tong, CW, Hong, J-S, et al.. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord 2002;17:116–24. https://doi.org/10.1002/mds.10078.Search in Google Scholar PubMed

134. Ling, Z, Zhu, Y, Tong, C, Snyder, JA, Lipton, JW, Carvey, PM. Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally. Exp Neurol 2006;199:499–512. https://doi.org/10.1016/j.expneurol.2006.01.010.Search in Google Scholar PubMed

135. Choudhury, ME, Kigami, Y, Tanaka, J. Dual roles of microglia in the basal ganglia in Parkinson’s disease. Int J Mol Sci 2021;22:3907. https://doi.org/10.3390/ijms22083907.Search in Google Scholar PubMed PubMed Central

136. Brydon, L, Harrison, NA, Walker, C, Steptoe, A, Critchley, HD. Peripheral inflammation is associated with altered substantia nigra activity and psychomotor slowing in humans. Biol Psychiatr 2008;63:1022–9. https://doi.org/10.1016/j.biopsych.2007.12.007.Search in Google Scholar PubMed PubMed Central

137. O’Connor, JC, Lawson, MA, André, C, Moreau, M, Lestage, J, Castanon, N, et al.. Lipopolysaccharide-induced depressive-like behavior is mediated by indoleamine 2,3-dioxygenase activation in mice. Mol Psychiatr 2009;14:511–22. https://doi.org/10.1038/sj.mp.4002148.Search in Google Scholar PubMed PubMed Central

138. Clement, HW, Buschmann, J, Rex, S, Grote, C, Opper, C, Gemsa, D, et al.. Effects of interferon-γ, interleukin-1β, and tumor necrosis factor-α on the serotonin metabolism in the nucleus raphe dorsalis of the rat. J Neural Transm 1997;104:981–91. https://doi.org/10.1007/bf01273312.Search in Google Scholar

139. Müller, T, Dürk, T, Blumenthal, B, Grimm, M, Cicko, S, Panther, E, et al.. 5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo. PLoS One 2009;4:e6453.10.1371/journal.pone.0006453Search in Google Scholar PubMed PubMed Central

Received: 2024-05-31
Accepted: 2024-06-18
Published Online: 2024-08-09
Published in Print: 2024-09-25

© 2024 the author(s), published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution 4.0 International License.

Articles in the same Issue

  1. Frontmatter
  2. Brief Report
  3. Elevated cerebral oxygen extraction in patients with post-COVID conditions
  4. Review Articles
  5. Build muscles and protect myelin
  6. Cannabis use, oral dysbiosis, and neurological disorders
  7. Sedation with midazolam in the NICU: implications on neurodevelopment
  8. The challenges to detect, quantify, and characterize viral reservoirs in the current antiretroviral era
  9. Research Articles
  10. Biodegradable cannabidiol: a potential nanotherapeutic for neuropathic pain
  11. Motivational dysregulation with melanocortin 4 receptor haploinsufficiency
https://doi.org/10.1515/nipt-2024-0012
Keywords for this article
cannabis; microbiome; dysbiosis; central nervous system; mental health
Creative Commons
BY 4.0

Articles in the same Issue

  1. Frontmatter
  2. Brief Report
  3. Elevated cerebral oxygen extraction in patients with post-COVID conditions
  4. Review Articles
  5. Build muscles and protect myelin
  6. Cannabis use, oral dysbiosis, and neurological disorders
  7. Sedation with midazolam in the NICU: implications on neurodevelopment
  8. The challenges to detect, quantify, and characterize viral reservoirs in the current antiretroviral era
  9. Research Articles
  10. Biodegradable cannabidiol: a potential nanotherapeutic for neuropathic pain
  11. Motivational dysregulation with melanocortin 4 receptor haploinsufficiency
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 25.10.2025 from https://www.degruyterbrill.com/document/doi/10.1515/nipt-2024-0012/html
Scroll to top button